New mammalian cell culture facility
A new mammalian cell culture cGMP manufacturing facility has been opened in Billingham, Teesside by Fujifilm Diosynth Biotechnologies.
The new facility – commissioned and built within 15 months – is the first of its kind in the UK, and was purpose-built to utilise primary single-use technologies for both upstream and downstream operations. It is home to a 200L and 1000L bioreactor, with a 2000L bioreactor planned for 2014.
“I am delighted that we have been able to build and commission our new GMP mammalian cell culture manufacturing facility in such a short time frame,” said Steve Bagshaw, Managing Director of Fujifilm Diosynth Biotechnologies. “This new capacity, using the latest single-use technologies, provides our customers with a full life-cycle offering for mammalian cell culture biopharmaceuticals from our UK site, and complements our offering in microbial-based biologics.”
The facility is the latest in a series of investments in both the UK and USA totalling £30m over the last two years.
Related Content
When plasma leaves the laboratory
The orbital laboratory is evolving into something more ambitious, a controlled industrial environment for producing next-generation materials, explains Ed Smith and Andrew Griffiths. …
Stratech acquisition signals further expansion for Europa Biosite
Cambridge Bioscience has purchased its fellow life sciences product distributor Stratech Scientific, in a move that further extends the reach …
Biosimilars and the post-patent environment
The market and frameworks for biologics and their biosimilars are growing and ever-evolving, as illustrated by the news around rheumatoid …
